Form 4: Maravai LifeSciences Director Receives Significant Restricted Stock Unit Grant

Maravai LifeSciences Holdings, Inc. Director Benjamin Daverman acquired 89,139 shares of Class A Common Stock through a restricted stock unit grant on June 16, 2025, increasing his indirect beneficial ownership.

Summary

• Benjamin James Daverman, a Director of Maravai LifeSciences Holdings, Inc. (MRVI), acquired 89,139 shares of Class A Common Stock.
• The transaction occurred on June 16, 2025, at an acquisition price of $2.16 per share.
• These shares represent restricted stock units awarded under the company's 2020 Omnibus Incentive Plan.
• The restricted stock units are set to vest in full upon the earlier of one year from the grant date or the date of the 2026 annual meeting of stockholders.
• Following this transaction, Mr. Daverman's indirect beneficial ownership in Maravai LifeSciences Holdings, Inc. stands at 138,055 shares.
• Mr. Daverman holds these securities for the benefit of a GTCR-affiliated entity and disclaims any pecuniary interest in them.

Sentiment

Score: 7

Explanation: The filing indicates a routine grant of restricted stock units to a director, which is generally viewed positively as it aligns management incentives with shareholder interests. The director's disclaimer of pecuniary interest due to holding for a GTCR-affiliated entity is a standard disclosure for such arrangements.

Positives

• Director Benjamin Daverman received a grant of 89,139 restricted stock units, which generally aligns his interests with shareholder value.
• The grant is part of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, indicating an established framework for incentivizing key personnel.

Negatives

• No explicit negatives identified in the filing.

Risks

• NA

Future Outlook

The restricted stock units are scheduled to vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Management Comments

• "Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders."
• "The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16."

Industry Context

This filing is a standard insider transaction report, reflecting an equity award to a director, which is a common practice in publicly traded companies across various industries to align management and director incentives with shareholder interests.

Comparison to Industry Standards

• NA

Related Party Transactions

• Benjamin Daverman holds the reported securities for the benefit of a GTCR-affiliated entity, disclaiming pecuniary interest in them.

Stakeholder Impact

• Shareholders: The grant of restricted stock units to a director aligns the director's interests with shareholder value, potentially encouraging long-term performance.
• Employees: The mention of the 2020 Omnibus Incentive Plan suggests a framework for equity compensation that may also apply to other employees.

Next Steps

• Vesting of 89,139 restricted stock units upon the earlier of June 16, 2026, or the date of the 2026 annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership, GTCR